Identifying somatic mutations for tumor profiling
Every cancer cell has its own pattern of mutated genes. This results in each cancer case, and even parts of the tumor, to be individual with respect to diagnosis, prognosis and treatment response.
The presence of recurrent somatic mutations allows us to create a detailed molecular fingerprinting of the tumor and to identify important diagnostic tumor subtypes.
What do we know about somatic mutations?
Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer can be the result of a genetic predisposition that is inherited from family members (germline (hereditary) gene mutation) or it can be the result of the acquired mutations accumulated during a lifetime (somatic (acquired) mutation). Most cancers are is independent of a germline (hereditary) mutation.
Unlike regular cells, cancer cells do not experience physiological elimination of “programmed cell death” or “apoptosis”; instead they continue to grow and divide. Tumor cells show uncontrolled proliferation if there are mutations in the genes involved in cell division .
How can somatic genetic testing help patient care?
Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patients tumor profile.
Why choose CENTOGENE?
Covers the 63 most important genes and more than 1,000 mutations associated with solid tumors.
Targets the 2,800 most common cancer-causing mutations in the 49 most common cancer-causing genes.
Covers 54 of the most important genes and more than 1,000 mutations associated with myeloid tumor.
Methodological summary of CENTOGENE’s somatic mutation testing
- Panel: Bi-directional NGS sequencing for all genes included in the panels (listed here below)
Single gene: Bi-directional sequencing for somatic mutations associated for this gene
- Panel: NGS panel analysis with complete 100% coverage for the target regions (technical accuracy of <98.1%)
Single gene: Sequencing is with 96.5% coverage for the target regions (technical accuracy of <98.1%)
- For every panel gene and full gene analysis, the complete coding sequence, exon/intron boundaries 10 bp into the intron, relevant promoter gene regions and all HGMD described pathogenic variants are analyzed, with subsequent variant validation for any clinically relevant genetic variant detected.
Our medical and genetic experts can help determine which genetic testing is right to analyze the risk for hereditary cancer syndromes. After testing, result evaluation and specific recommendations for each individual case are necessary to decide on further steps for full patient care.
Downloads for somatic mutation testing
One pager - Acute myeloid leukemia tumor panelDownload
One pager - BRCA1/ BRCA2 somatic mutation analysisDownload
One pager - Colorectal cancer solid tumor panelDownload
One pager - GIST/ GI solid tumor panelDownload
One pager - Lung cancer solid tumor panelDownload
Request form - Oncogenetic diseasesDownload
Our portfolio for somatic mutation testing
Latest scientific articles
Pancreatic cancer is one of the world’s most lethal malignant neoplasms, with a 5-year survival rate of about 5-7%. Pancreatic cancer now represents the fourth to fifth most frequent cause of cancer mortality in North…
Looking for a one-stop-solution for your laboratory? Join this webinar to learn more about our CentoCloud® for diagnostic NGS panels, clinical bioinformatics & medical interpretation in the oncogenetic workflow.
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant susceptibility for diffuse gastric cancer, a poorly differentiated adenocarcinoma localized in the stomach wall. Gastric cancer is one of the most common…